New research has shown that triple-negative breast cancer is fuelled by lipids and fatty acids that are a key feature of ...

Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...

A genome-wide study of over 200,000 Estonians has revealed genetic variants linked to appetite and body weight. The findings ...

Elevated early-onset cancer incidence is accompanied by similar increases in older adults as well, and that rising obesity ...

Two biopharma companies launched within the past year raised top amounts in series B financings for 2025, seeking to advance ...

A study finds women with metabolic syndrome are at higher risk for gynaecological cancers, emphasizing the need for preventive measures and research in India. | Mumbai news ...

GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

Most effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline says Certain GLP-1 drugs are best for specific complications The non-binding guideline ...

As obesity continues to drive cardiovascular risk, the ACC has released two new guidance documents to support clinicians: Concise Clinical Guidance (CCG) on the medical management of obesity and a ...

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The company cited strategic ...